Investigating changes in β-adrenergic gene expression (ADRB1 and ADRB2) in Takotsubo (stress) cardiomyopathy syndrome; a pilot study

Serap Tutgun Onrat1 · İbrahim Etem Dural2 · Zafer Yalım2 · Ersel Onrat2

Received: 27 July 2021 / Accepted: 7 October 2021 / Published online: 29 October 2021
© The Author(s), under exclusive licence to Springer Nature B.V. 2021

Abstract
Background  Takotsubo Cardiomyopathy (TC) is a rare disorder that is mostly caused by stress and is often misdiagnosed. We aimed to analyze Takotsubo Syndrome at the molecular level by using the Oxford Nanopore Minion Device and its protocol.
Methods and results  Ten patients who were previously diagnosed with Takotsubo Syndrome (increased after decrease in ejection fraction and without critical stenosis in coronary arteries) and 10 healthy individuals in the control group were included in our project. The mean age was 53 ± 12.2 for the patient group and 52.4 ± 9.9 for the control group, and the left ventricular ejection fraction was 50.3 ± 11.5 for the patient group and 64.2 ± 2.8 for the control group (p < 0.05). Peripheral blood of patients and healthy individuals was taken and their DNA was obtained. By making long reads throughout the genome, the most studied regions responsible for β-adrenergic signaling pathways; The gene expression level of cardiac β-1 ADRB1 (rs1801253-ENST00000369295.4), G > C, (Gly389Arg) and cardiac β-2 ADRB2 (rs1800888-ENSG00000169252), C > T, (Thr165Ile) adrenoceptors was investigated. As a result; no structural variation was detected leading to Takotsubo Cardiomyopathy. The results obtained from the bioinformatics analysis were also checked from the VarSome Tools and similar results were found.
Conclusions  Many publications in TC susceptibility have that may lead to adrenergic pathway dysregulation, most studied adrenergic receptor genes in the similar literatures too. We searched for genetic variants in b1AR and b2AR genes in our study and however we could not find any variants in this study, we think larger numbers of cohort studies are needed.

Keywords  Takotsubo · Cardiomyopathy · Stress · ADRB1 · ADRB2 · Exome

Introduction
Takotsubo cardiomyopathy (TC) is a reversible cardiomyopathy defined by the apical balloon appearance of the left ventricle, which has been identified for nearly 25 years. The syndrome was named “Takotsubo” to describe the enlargement of the left ventricle, due to its resemblance to the ear-rings used by the Japanese to catch octopuses. Stress cardiomyopathy is a rare acute reversible heart failure syndrome that may be associated with serious complications. Although awareness and diagnosis have increased in recent years, the true incidence is still unknown in our country and all over the world. The incidence of cases is estimated to be between 15 and 30 per 100,000 per year data from the United States and Europe cohorts [1, 2]. Catecholamine increase plays an important role in the pathophysiology of TC; for this reason, it is also called “Stress Cardiomyopathy” [3]. It causes TC, which is a disease in which the effects of physical and
psychological stress are also seen, to gain different characteristics from known cardiomyopathies [4, 5].

It is usually seen in the postmenopausal period of women, after emotional or physical stress [6]. They reported that it is more common in the postmenopausal period because the drop in estrogen makes the heart more sensitive to catecholamines, and hence systolic dysfunction can develop more easily in the left ventricle of the heart under stress [7]. Increased catecholamine levels are thought to have a crucial role, despite the fact that its physiopathology is unknown yet (Fig. 1a). In addition, myocardial enlargement, hypertension, chronic obstructive pulmonary disease, decrease in estrogen level, small vessel disease, myocarditis, insufficiency of myocardial fatty acid metabolism are also accompanied. Symptoms and electrocardiogram (ECG) findings mimic acute coronary syndrome [5, 6].

Acute changes in myocardial function are predominantly controlled by the beta-adrenergic receptor (β-AR) and occasionally result in changes in an intracellular signaling pathway [8]. Specifically, transmissions in signal transduction pathways triggered by the agonist response of β-ARs act as essential regulators of heart rate, systolic and diastolic function, and myocardial metabolism [9, 10].

Until now, all major genome sequencing technologies have been used as modifications of polymerase-mediated DNA synthesis. While these methods have contributed immensely to our genome recognition so far, nanopore-based sequencing is a new technology that represents entirely different genome-wide read-along approaches in which nucleic acid sequences are inferred from changes in ionic current across a membrane as a single DNA molecule passes through a protein nanopore [11].

Genetic variation in both ADRB1 and ADRB2 has been associated with disease phenotypes, both in vitro and clinically. Recent studies are: they are studies investigating the potential interaction between variations in ADRBs and drugs for these important receptors [12, 13]. In our study, we aimed to investigate whether there is any variation in ADRB1 and ADRB2 genes in the patient and control group diagnosed with Takotsubo Cardiomyopathy using Nanopore technology. Beta-adrenergic receptors (ADRBs) are cell surface receptors that play a central role in the sympathetic nervous system. The pharmacological selection of two of these receptors, ADRB1 and ADRB2, is due to the fact that they can be evaluated for a widely used therapeutic approach for common and important diseases such as asthma, hypertension and heart failure.
Materials and methods

Patients

Within the framework of the project, 10 patients who were admitted to Afyonkarahisar Health Sciences University, Faculty of Medicine, Department of Cardiology and hospitalized with the diagnosis of acute coronary syndrome or acute heart failure and diagnosed with Takotsubo Cardiomyopathy according to the diagnostic criteria of Mayo Clinic TK, included in the study. As the control group, 10 healthy individuals included in the study. Medical history, physical examination, laboratory findings, electrocardiography, echocardiography, coronary angiography and ventriculography of the patients were evaluated. 10 ml of venous blood samples taken from the forearm with the vacutainer system from the patients were transferred to the Medical Genetics Department on the same day. This study was performed according to the Declaration of Helsinki II. All participants provided and signed informed consent and were approved by the Institutional Local Ethics Committee.

One of the 20 subjects (10 patients and 10 controls) diagnosed with Takotsubo Cardiomyopathy included in the study did not want to donate blood. Genomic DNA (gDNA) was obtained from a total of 18 cases (9 patients and 9 controls) using the QIAamp DNA Blood Mini Kit (Qiagen) and quantified with the NanoDrop ND-1000 Spectrophotometer. Therefore, the number of control groups was started to be 9 to equalize the number of study and control groups. In our study group, menopausal women are more affected by Takotsubo cardiomyopathy, so the number of male cases is less. The characteristics of the demographic and clinical variables of the study and control groups are given in Table 1, and the echocardiographic results of our study and control groups are given in Table 2.

Library prep with native barcoding amplicons

Library preparation was completed using the Native Barcoding Kit 1D (catalog number EXP-NBD104) and Ligation Sequencing Kit (catalog number SQK-LSK109; Oxford Nanopore Technologies, Oxford, UK) (Fig. 1b). ONT libraries were prepared as follows: 48 μl of genomic DNA per library was 3.5 μl of NEBNext FFPE DNA Repair Buffer, 2 μl of NEBNext FFPE DNA Repair Mix (New England Biolab, M6630), and 3.5 μl of nuclease-free water (NFW) and incubated at 20 °C for 15 min for DNA repair, re-pooled and cleaned up using a 0.8× volume of AMPure XP beads (Beckman Coulter) according to the manufacturer’s instructions, with final elution in 30 μl of EB (10 mM Tris pH 8.0).

The DNA recovered from the elution well (~40 μl) was brought to 50 μl and end-repaired by the addition of 3.5 μl

Table 1 Demographic and clinical characteristics of the study group

| Variables | Takotsubo (n:9) | Control (n:9) | P value |
|-----------|----------------|--------------|---------|
| Male      | 2 (%22.2)     | 3 (%33.3)    | 0.599   |
| Women     | 7 (%77.8)     | 6 (%66.7)    |         |
| Age (years) | 53 ±12.2   | 52.4 ±9.9   | 0.917   |
| BMI (kg/m²) | 28.6 ±4.06 | 27.6 ±4.09  | 0.616   |
| HT        | 2 (%22.2)     | 2 (%22.2)    | 1       |
| DM        | 3 (%33.3)     | 1 (%11.1)    | 0.257   |
| Throid Dys | 0            | 1 (%11.1)    | 0.303   |
| Total cholesterol, mg/dl | 161.5 ±45.8 | 204.5 ±65   | 0.125   |
| Triglicerid (mg/dl) | 182.2 ±80.5  | 141.3 ±60.5 | 0.255   |
| HDL cholesterol (mg/dl) | 43.3 ±17    | 51.5 ±12.5  | 0.261   |
| LDL cholesterol (mg/dl) | 101.5 ±44.3 | 155.7 ±60.3 | 0.045   |
| White blood cell count, µl | 10.09 ±1.6  | 7.3 ±2.1   | 0.007§  |
| Haemoglobin, g/dl | 13.9 ±1.7   | 13.8 ±1.6  | 0.891   |
| Platelet, 10³/mm³ | 292.4 ±75.4 | 276 ±91.3  | 0.683   |
| Lymphocyte count, µl | 2.7 ±0.8    | 2.5 ±0.5   | 0.560   |
| Neutrophil count, µl | 6.3 ±1.7    | 3.8 ±1.7   | 0.009§  |
| Monocyte count, µl | 0.67 ±0.098 | 0.59 ±0.17 | 0.261   |
| ALT       | 22.1 ±12.4    | 24.4 ±16.4  | 0.739   |
| AST       | 19.2 ±4.6     | 24.1 ±9.1   | 0.173   |
| Creatinine | 0.8 ±0.2    | 0.7 ±0.16   | 0.559   |
| F.glukoz  | 117.3 ±27.7   | 100.7 ±7.1  | 0.102   |
| TSH       | 1.5 ±1.1      | 1.6 ±0.8    | 0.720   |
| T4        | 1.3 ±0.18     | 1.2 ±0.21   | 0.411   |
| C-reactive protein, mg/dl | 0.4 ±0.27  | 0.3 ±0.19  | 0.425   |

Table 2 Echocardiographic results of the Study and Control groups

| Variables | Takotsubo (n:9) | Control (n:9) | P value |
|-----------|----------------|--------------|---------|
| LVEDD (mm) | 47.5 ±4.9   | 44.2 ±1.7   | 0.072   |
| LVESD (mm) | 33.2 ±7.8   | 27.7 ±1.5   | 0.059   |
| LVEF Simpson (%) | 50.3 ±11.5 | 64.2 ±2.8   | 0.003§ |
| IVS (mm) | 11.5 ±1.58   | 11.1 ±1.53  | 0.555   |
| PW (mm) | 10.8 ±1.53   | 10.6 ±1.1   | 0.730   |
| LA (mm) | 34.1 ±3.8    | 32.2 ±4.7   | 0.372   |
| A0 (mm) | 25 ±2.1      | 26 ±2.1     | 0.339   |

LVEDD left ventricular end diastolic diameter, LVESD left ventricular end systolic diameter, LVEF left ventricular ejection fraction, IVS interventricular septum, PW posterior wall, LA left atrium, A0 Aort root diameter, n number

*p < 0.05 statistical significance

NEBNext Ultra II End Prep Reaction Buffer and 3 μl NEBNext Ultra II End Prep Enzyme Mix (New England Biolab, E7546) with incubation for 5 min at 20 °C followed by 5 min at 65 °C. The sample was cleaned up with 1× volume AMPure XP beads and eluted in 30 μl of EB.
PCR adapters (20 μl) from Oxford Nanopore Technology (SQK-LSK 109 Ligation Sequencing Kit 1D) were ligated to the end-repaired DNA with 50 μl of NEB Blunt/TA Ligase Master Mix (M0367) at room temperature for 10 min, followed by clean-up with 1 x volume AMPure XP beads and elution in 48 μl of EB.

Combined 22.5 μl of purified DNA, 2.5 μl of Native Barcode and 25 μl of blunt/TA ligase master mix in a new 1.5 ml DNA-low binding reaction tube, mix was by tapped and spined briefly. It was incubated for 10 min at room temperature. Then 65 μl pooled barcoded DNA, 5 μl Adapter MixII (AMII), 20 μl NEBNext Quick Ligation Buffer (5x) and 10 μl Quick T4 DNA Ligase were prepared for Adaptor ligation and clean-up steps, and mix was gently by flicked the tube and spin down. Finally, 61.5 ng/ml of the control group and 58.8 ng/ml of the patient group's pooled DNA were washed twice with 250 μl of Short Fragment Buffer (SFB) Buffer and loaded into the MinION device by adding 15 μl of Elution Buffer. In a new tube, prepared the library for loading as follows; 37.5 μl Sequencing Buffer(SQB), 25.5 μl Loading Beads, ~14 μl DNA library. Then gently loaded SpotOn Flowcell. As the first operation; Flow-Check was performed to check pore numbers, then samples were loaded separately as study and control groups using the MinION Mk1b sequencer with two FLO-MINSP6 flow cells. Assuming the sample count as 10, respectively, 1M reads with an average length of 100,000 bases were obtained. Raw data (FAST5 files) were obtained using MinKNOW software version 21.06.0 (Oxford Nanopore Technologies), which were converted to FASTQ files and sorted into each sample depending on their barcode sequences by using Guppy software version 4.4.0 (Oxford Nanopore Technologies).

Data analysis

The data obtained as a result of MinION (Oxford Nanopore Technologies) sequencing were processed in fast5 format. In the first stage, basecalling and demultiplexing operations of fast5 files were performed with Guppy basecaller 4.4.0 software, and the obtained sequences were obtained in fastq format and separated into barcodes. Sequences in fastq format were loaded into the Geneious Prime 2021.0.3 (www.geneious.com) program in separate files according to each barcode, and the sequences consisting of different fragments with the same barcode were combined. The sequences were made ready for the mapping process by performing filtering processes according to the quality scores of the obtained sequences. The reference sequence required for the mapping process was obtained after the analysis of the presented primers. Given for the ADRB1 gene; forward 5'-AGACGTGCTATGTTGACGG-3' and reverse 5'-AGC ACTTGGGGTGTCTGTTG-3' primer pair, given for the ADRB2 gene; forward 5'-TGGATTGTGCCGGCATTA-3' and reverse 5'-TGGACCGGTACCCAGTGC-3'.

Results

Demographic data of all participants are seen in Table 1. There was no difference in the all parameters between two groups. Echocardiographic results of our study and control groups are given in Table 2. Ten patients who were previously diagnosed with Takotsubo Syndrome (increased after decrease in ejection fraction and without critical stenosis in coronary arteries) and 10 healthy individuals in the control group were included in our project. The mean age was 53 ± 12.2 for the patient group and 52.4 ± 9.9 for the control group, and the left ventricular ejection fraction was 50.3 ± 11.5 for the patient group and 64.2 ± 2.8 for the control group (p < 0.05). Peripheral blood of patients and healthy individuals was taken and their DNA was obtained.

By making long reads throughout the genome, the most studied regions responsible for β adrenergic signaling pathways: The gene expression level of cardiac β-1 ADRB1 (rs1801253-ENST00000369295.4), G > C, (Gly389Arg) and cardiac β-2 ADRB2 (rs1800888-ENSG00000169252), C > T, (Thr165Ile) adrenoceptors was investigated. As a result; No structural variation was detected leading to Takotsubo Cardiomyopathy. The results obtained from the bioinformatics analysis were also checked from the VarSome Tools and similar results were found. The data of the alignment results of ADRB1 and ADRB2 gene regions according to the analysis are shown in Table 3. The results obtained show very high coverage and accuracy results for the ADRB1 region, but not significant results for the ADRB2 region. Therefore, the results and statistical information shown in the report apply only to the ADRB1 region.

Considering these matches, the gene region “Homo sapiens—NG_012187.1 Homo sapiens adrenoceptor beta 1 and 2 (ADRB1 and ADRB2), RefSeqGene on chromosome 10” was downloaded in full genbank format and pulled into Geneious Prime 2021.0.3 (www.geneious.com) (Fig. 2a and b).

Using these references, mapping for the sequences of each barcode was performed with the minimap2.17 software “Command Line: minimap2.exe-xmap-ont--frag=yes-k21 --secondary=yes-N5-p0.7-arefSeq.fastainput.fastq-output.fastq-0output.sam” commands.

While the results obtained showed very high coverage and accuracy results for the ADRB1 region, they did not yield any significant results for the ADRB2 region. Therefore, the results and statistical information shown in the report are inclusive only for the ADRB1 region.

The fasta file for each sample is additionally provided. The threshold value taken while creating fasta files was.
determined as coverage over 1000. Images of each alignment are given below in order. Statistical information is given as an appendix in the "stats.xlsx" file.

No significant changes were observed in the alignment analysis performed with the obtained consensus sequences. In the picture given (Fig. 2c and d), the multiple alignment graph made with the consensus sequences and the images taken by zooming the regions with the change in this graph are given.

### Discussion

Although the recovery rate in TC is high, hemodynamic and respiratory support may be required, and death may occur in some cases. A better understanding of the disease’s mechanisms can help with targeted management and improved survival. Identifying the role of genetic variants will aid in both understanding the abnormalities in these patients' signaling pathways and informing new therapeutic targets. In another study thought to be effective in Takotsubo syndrome; although there is no evidence for specific genetic variants in GRK5 or bAR that play a role in an individual's

### Table 3

Data of the Alignment results of ADRB1 and ADRB2 gene regions according to the analysis performed

| Analysis type | Primer F-R* | Barcode kiti | Barcode no | Sequencing Kit | Flowcell type | Received data size (MBfastq/barcode) | ADRB1 Aligned Read number | ADRB2 Aligned Read number |
|---------------|-------------|--------------|------------|----------------|---------------|--------------------------------------|--------------------------|--------------------------|
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD01 | SQK-LSK109 | FLO-MIN106 | 137 | 137701 | 7 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD02 | SQK-LSK109 | FLO-MIN106 | 183 | 165975 | 8 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD03 | SQK-LSK109 | FLO-MIN106 | 95 | 87236 | 8 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD04 | SQK-LSK109 | FLO-MIN106 | 168 | 156156 | 24 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD05 | SQK-LSK109 | FLO-MIN106 | 88 | 96652 | 3 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD06 | SQK-LSK109 | FLO-MIN106 | 35 | 37285 | 3 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD07 | SQK-LSK109 | FLO-MIN106 | 123 | 109483 | 19 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD08 | SQK-LSK109 | FLO-MIN106 | 66 | 72119 | 0 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD09 | SQK-LSK109 | FLO-MIN106 | 151 | 154890 | 11 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD01 | SQK-LSK109 | FLO-MIN106 | 114 | 121707 | 2 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD02 | SQK-LSK109 | FLO-MIN106 | 110 | 117779 | 6 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD03 | SQK-LSK109 | FLO-MIN106 | 131 | 143815 | 1 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD04 | SQK-LSK109 | FLO-MIN106 | 111 | 123712 | 0 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD05 | SQK-LSK109 | FLO-MIN106 | 118 | 124389 | 2 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD06 | SQK-LSK109 | FLO-MIN106 | 81 | 88196 | 1 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD07 | SQK-LSK109 | FLO-MIN106 | 118 | 127283 | 2 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD08 | SQK-LSK109 | FLO-MIN106 | 107 | 117082 | 2 |
| ADRB1-2 target region | ADRB1-ADRB2 | EXP-NBD104 | NBD09 | SQK-LSK109 | FLO-MIN106 | 157 | 169639 | 4 |

*F Primer: ADRB1 5’-AGACGTGCTATGTGTGACGG-3’ ADRB2 5’-TGGATTGTTGTCGGGCCCTTA-3’
R Primer: ADRB1 5’-AGCAGCTGGGTTGTTGAG-3’ ADRB2 5’-TGACCGGTACCAGTGCAT-3’*
susceptibility to TC, this has been proposed as an interesting hypothesis. Therefore, further exploration of alternative candidates in the proposed signaling pathways or non-candidate approaches such as genome-wide screening is recommended [14, 15].

It is most common in women during their postmenopausal period, following emotional or physical stress. They reported that the reason it is common in the postmenopausal period is that it makes the heart more sensitive to catecholamines as estrogen levels fall, and thus systolic dysfunction may develop more easily in the left ventricle of the heart under stress. Although its physiopathology is unknown, increased catecholamine levels are thought to play a significant role. Furthermore, enlarged myocardium, hypertension, chronic obstructive pulmonary disease, decreased estrogen level, small vessel disease, myocarditis, and insufficiency of myocardial fatty acid metabolism have all been implicated. Symptoms and electrocardiogram (ECG) findings are similar to those seen in acute coronary syndrome [16].

Sharkey et al. published their study in which they genotyped three adrenergic receptor polymorphisms in a cohort of 41 patients with stress cardiomyopathy (SK). This idiopathic but reversible disorder, also known as takotsubo cardiomyopathy and apical balloon syndrome, was typically seen in postmenopausal women. After acute emotional or physical stress, it was also manifested by ischemia-like chest pain, transient ECG changes, and minor cardiac biomarker elevation. Coronary arteries were not occluded in angiography of Takotsubo patients. Sharkey et al. investigated functional polymorphisms of B1 and alpha 2c adrenergic receptors. Despite increased sympathetic nervous system activation, which increases catecholamines (epinephrine, norepinephrine, and dopamine) and stimulates adrenergic receptors, it has been reported that there is no significant difference between Takotsubo patients and female controls when polymorphism frequencies are compared [17]. This result was similar our research results.

Figtree et al. examined the potential association of genetic variants in the adrenergic and estrogen signaling pathways with TC in a large cohort of 92 Takotsubo patients recruited from four major Australian centers. While genotypic variation is an attractive way to explain disease susceptibility, this study demonstrates that major candidate polymorphisms in adrenergic, estrogen, and GRK5 signaling pathways genes are not associated with TC [14].

Studies have led to the hypothesis that epinephrine is the main circulating catecholamine under stress, leading to the hypothesis that regional differences in epinephrine-sensitive B2 receptors may explain the myocardial response to the catecholamine surge seen in Takotsubo Cardiomyopathy [18]. Therefore, it has been hypothesized that its mutation in adrenergic receptors may increase the sensitivity of the heart to adrenergic stress. In polymorphism studies with primers designed for the ADRB1 and ADRB2 genes, comprehensive DNA sequencing of these adrenergic receptor genes did not reveal any mutations in the familial Takotsubo Cardiomyopathy case. While a molecular defect in adrenergic signaling remains a plausible pathogenic mechanism, our data, along with the findings of Sharkey et al., suggest that Takotsubo Cardiomyopathy is probably not based on genetic variation in adrenergic receptors [19, 20].

Eitel et al., in a large GWAS study; It has been concluded that the genes in the ±500 kb upstream and downstream regions of the SNPs in the gene regions that are thought to cause TC may be associated with different cancer types, obesity and heart rate variability, but cannot be directly responsible for TC. According to these
results; although there is a familial predisposition for TC in several families, or studies have been conducted in postmenopausal women; it has been reported that larger-scale TC cohorts should be established [21]. In a study in rats; Expression of β-1AR and β-2AR mRNA in Dilated Cardiomyopathies treated with doxorubicin was evaluated by RT-qPCR and reported no change in β-1AR and β-2AR gene expressions [22].

Although a few familial cases of Takotsubo have been reported, no responsible gene mutation, variation or polymorphism has been clearly identified so far, so the genetic causes underlying TC have not yet been clearly elucidated.

Conclusion

Beta1-adrenergic receptors (beta1ARs) are interesting candidates for pharmacogenetic studies, particularly in heart disease, as they mediate the action of catecholamines in the sympathetic nervous system. These receptors are important both in the progression of the disease and in its treatment (beta blocker therapy). For this reason, it has been a matter of curiosity what kind of changes occur in gene expression levels [12]. From the results of studies to date, it has been considered very likely that beta1AR variants have a genetic component that defines the response to beta-blockers in heart failure and hypertension. However, due to the inconsistency in the results of the polymorphism study, the polymorphism results cannot be used in practice yet, and we did not find any variation in the ADRB1 and ADRB2 genes in our study. Therefore, multicenter studies with different races and a large number of patients are needed.

Limitations

The major limitation of this study was the small sample size and single-center design. Although we collaborated with many different clinics to identify these patients, our sample size was small, possibly due to the Covid-19 pandemic. Nevertheless, we think that our study is important because our data show the frequency of this disease in our city and provide pilot data to investigate the effect of β-Adrenergic Gene Expression alteration.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11033-021-06816-w.

Acknowledgements The study was supported by grants from the Science Faculty of Afyonkarahisar Health Science University Research Project Commission and the project number is 20.GENEL.006.

Author contributions ZY and STO designed and performed the experiments, analysed data, and wrote the manuscript. EO, ZY and IED performed polyclinic examinations, Takotsubo Cardiomyopathies diagnosis and other cardiological datas.

Funding The study was supported by grants from the Afyonkarahisar Health Science University Research Project Commission and the project number is 20.GENEL.006.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval The studies were approved Ethics Committee of Afyonkarahisar Health Science University.

Consent for publication All authors approved the final manuscript and agreed to publication in Basic Research in Cardiology.

References

1. Chazal HM, Buono MG, Keyser-Marcus L, Ma L, Moeller FG, Berrocal DAA (2018) Stress cardiomyopathy: diagnosis and treatment. J Am Coll Cardiol 16:1955–1971. https://doi.org/10.1016/j.jacc.2018.07.072
2. Brinjikji W, El-Sayed AM, Salka S (2012) In-hospital mortality among patients with takotsubo cardiomyopathy: a study of the National Inpatient Sample 2008 to 2009. Am Heart J 164:215–221. https://doi.org/10.1016/j.ahj.2012.04.010
3. Akashi YJ, Ishihara M (2016) Takotsubo syndrome: insights from Japan. Heart Fail Clin 12:587–595. https://doi.org/10.1016/j.hfcl.2016.06.009
4. Amin HZ, Amin LZ, Pradipta A (2020) Takotsubo cardiomyopathy: a brief review. J Med Life 13:3–7. https://doi.org/10.25122/jml-2018-0067
5. Mattsson E, Saliba-Gustafsson P, Ehrenborg E, Tornvall P (2018) Lack of genetic susceptibility in takotsubo cardiomyopathy: a case-control study. BMC Med Genet 19:1–7. https://doi.org/10.1186/s12881-018-0544-6
6. Boyd B, Solhi T (2020) Takotsubo cardiomyopathy: review of broken heart syndrome. J Am Acad Phys Assist 33:24–29. https://doi.org/10.1097/01.JAA.0000654368.35241.fc
7. Ahmari N, Schmidt JT, Krane GA, Malphurs W, Cunningham BE, Owen JL, Martyniuk CJ, Zubcevic J (2016) Loss of bone marrow adrenergic beta 1 and 2 receptors modifies transcriptional networks, reduces circulating inflammatory factors, and regulates blood pressure. Physiol Genom 48:526–536. https://doi.org/10.1152/physiogenomics.00039.2016
8. Pelliccia F, Greco C, Vitale C, Rosano G, Gaudio C, Kaski JC (2014) Takotsubo syndrome (stress cardiomyopathy); an intriguing clinical condition in search of its identity. Am J Med 127:699–704. https://doi.org/10.1016/j.amjmed.2014.04.004
9. Limongelli G, D’Alessandro R, Masarone D, Maddaloni V, Vriz O, Minisini R, Citro R, Calabrò P, Russo MG, Calabrò R, Pacileo G, Bossone E, Elliott PM (2013) Takotsubo cardiomyopathy: do the genetics matter? Heart Fail Clin 9:207–216. https://doi.org/10.1016/j.hfc.2012.12.008
10. Zaroff JG, Pawlikowska L, Miss JC, Yarlagadda S, Ha C, Achrol A, Kwok P-Y, Mcculloch CE, Lawton MT, Ko N, Smith W, Young WL (2006) Adrenergic receptor polymorphisms and the risk of cardiac
injury and dysfunction after subarachnoid hemorrhage. Stroke 37:1680–1685. https://doi.org/10.1161/01.STR.000026461.52423.dd

11. Bowden R, Davies RW, Heger A, Pagnamenta AT, de Cesare M, Oikkonen LE, Parkes D, Freeman C, Dhalla F, Patel SY, Popitsch N, Ip CLC, Roberts HE, Salatino S, Lockstone H, Lunter G, Taylor JC, Buck D, Simpson MA, Donnelly P (2019) Sequencing of human genomes with nanopore technology. Nat Commun 10:1–9. https://doi.org/10.1038/s41467-019-09637-5

12. Taylor MRG (2007) Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenomics J 7:29–37. https://doi.org/10.1038/sj.tpj.6500393

13. Vriz O, Minisini R, Citro R, Guerra V, Zito C, De Luca G, Pavan D, Pirisi M, Limongelli G, Bossone E (2011) Analysis of β1 and β2-adrenergic receptors polymorphism in patients with apical ballooning cardiomyopathy. Acta Cardiol 66:787–790. https://doi.org/10.1080/ac.66.6.2136964

14. Figtree GA, Bagnall RD, Abdulla I, Buchholz S, Galougahi KK, Yan W, Tan T, Neil C, Horowitz JD, Semsarian C, Ward MR (2013) No association of G-protein-coupled receptor kinase 5 or β-adrenergic receptor polymorphisms with Takotsubo cardiomyopathy in a large Australian cohort. Eur J Heart Fail 15:730–733. https://doi.org/10.1093/eurjhf/hft040

15. Novo G, Giambanco S, Guglielmo M, Arvigo L, Sutera MR, Giambanco F, Evola S, Vaccarino L, Bova M, Lio D, Assemmato P, Novo S (2015) G-protein-coupled receptor kinase 5 polymorphism and Takotsubo cardiomyopathy. J Cardiovasc Med 16:639–643. https://doi.org/10.10245/JCM.0000000000000120

16. Pernicova I, Garg S, Bourantas CV, Alamgir F, Hoye A (2010) Takotsubo cardiomyopathy: a review of the literature. Angiology 61:166–173. https://doi.org/10.1177/0003319709335029

17. Sharkey SW, Maron BJ, Nelson P, Parpurt M, Maron MS, Bristow MR (2009) Adrenergic receptor polymorphisms in patients with stress (tako-tsubo) cardiomyopathy. J Cardiol 53:53–57. https://doi.org/10.1016/j.jjcc.2008.08.006

18. Lyon AR, Rees PSC, Prasad S, Poole-Wilson PA, Harding SE (2008) Stress (Takotsubo) cardiomyopathy—a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 5:22–29

19. Handy AD, Prasad A, Olson TM (2009) Investigating genetic variation of adrenergic receptors in familial stress cardiomyopathy (apical ballooning syndrome). J Cardiol 54:516–517. https://doi.org/10.1016/j.jjcc.2009.08.008

20. Cotecchia S (2010) The α1-adrenergic receptors: Diversity of signaling networks and regulation. J Recept Signal Transduct 30:410–419. https://doi.org/10.1177/0003319709335029

21. Eitel I, Moeller C, Munz M, Stiermaier T, Meitingen T, Thiele H, Erdmann J (2017) Genome-wide association study in takotsubo syndrome—preliminary results and future directions. Int J Cardiol 236:335–339. https://doi.org/10.1016/j.ijcard.2017.01.093

22. Vasić M, Lončar-Turukalo T, Tasić T, Matić M, Glumac S, Bajić D, Popović B, Japundžić-Žigon N (2019) Cardiovascular variability and β-ARs gene expression at two stages of doxorubicin-induced cardiomyopathy. Toxicol Appl Pharmacol 362:43–51. https://doi.org/10.1016/j.taap.2018.10.015

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.